Hi Tech Pharmacal (Nasdaq: HITK) is expected to report Q3 earnings on March 7. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Hi Tech Pharmacal's revenues will grow 8.7% and EPS will decrease -10.1%.

The average estimate for revenue is $60.5 million. On the bottom line, the average EPS estimate is $0.71.

Revenue details
 Last quarter, Hi Tech Pharmacal tallied revenue of $57.5 million. GAAP reported sales were 1.2% higher than the prior-year quarter's $56.9 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, EPS came in at $0.66. GAAP EPS of $0.66 for Q2 were 37% lower than the prior-year quarter's $1.04 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 51.4%, 730 basis points worse than the prior-year quarter. Operating margin was 22.6%, much worse than the prior-year quarter. Net margin was 15.5%, 870 basis points worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $235.1 million. The average EPS estimate is $2.62.

Investor sentiment
 The stock has a four-star rating (out of five) at Motley Fool CAPS, with 204 members out of 219 rating the stock outperform, and 15 members rating it underperform. Among 48 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 42 give Hi Tech Pharmacal a green thumbs-up, and six give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Hi Tech Pharmacal is outperform, with an average price target of $36.83.